Abstract 4989
Background
Gastric cancer (GC) is one of the most common lethal malignancies worldwide. Signet ring cell carcinoma (SRCC) is a poorly differentiated gastric cancer. The molecular characteristics and prognostic of SRCC are not well studied.
Methods
Formalin fixed paraffin embedded (FFPE) samples of 64 Chinese solid tumor patients were collected for next‐generation sequencing (NGS) based 450 genes panel assay. Genomic alterations including single base substitution, short and long insertions/deletions, copy number variations, gene fusions and rearrangement were assessed. Microsatellite stable (MSS) status and TMB (tumor mutational burden) were also acquired by an NGS algorithm.
Results
A total of 64 patients were identified as GC-SRCC through SRCC histology. The most frequently mutated genes were TP53(48%), CDH1(31%), ARID1A(14%), CDKN2A(9%), LRP1B(9%), KMT2D(6%), NF1(6%), ERBB2(9%) and GLI3(8%). Meanwhile, the copy numbers of FGFR2(14%), FGF3(8%), FGF19(8%), FGF4(8%), MYC(8%), CCND1(6%) and CDKN2A(9%) were frequently altered in SRCC.FGFR2 and 11q13 amplification is the first time reported in Chinese SRCC. Moreover, FGFR2 rearrangement (FGFR2/VTI1A and FGFR2/TACC2) was detected in 4% tumor samples. 34 cases had received chemotherapy, 4 cases had confirmed partial responses (PR); 14 cases had reached the stability of disease (SD). Noticeably, patients harboring gene rearrangement (N = 9) were observed a much shorter overall survival time (OS) in comparison with patients without any gene rearrangement (N = 14) (13.2 months vs 24.2 months, P < 0.05). Additionally, patients with CDH1 mutation (N = 9) showed a shorter OS than CDH1 wide type (N = 25) (14.2 months vs 25.3 months, P = 0.11), although the difference was not statistically significant.
Conclusions
Our observation reveals the molecular characteristics of SRCC. Gene rearrangements might associate to shorter OS. FGFR2 and 11q13 region amplification were newly observed in SRCC. It might provide new possibilities for the treatment of SRCC. Due to the limitations of the number of samples, the results may require further research and validation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4732 - Progesterone Receptor Isoform Ratio Dictates Antiprogestins/Progestins Effects on Metastatic Breast Cancer Models
Presenter: Maria Abascal
Session: Poster Display session 2
Resources:
Abstract
5737 - PAM50 and CGH-array genomic characterization of HER2-Equivocal Breast Cancers defined by the 2018 ASCO/CAP recommendations.
Presenter: Carine Ngo
Session: Poster Display session 2
Resources:
Abstract
1096 - OncotypeDX® predictive nomogram for recurrence score output: a machine learning system based on quantitative immunochemistry analysis - ADAPTED01
Presenter: Fabio Marazzi
Session: Poster Display session 2
Resources:
Abstract
5426 - Geriatric parameters predict both disease-related and patient-reported outcomes in older patients with breast cancer
Presenter: Willeke van der Plas-Krijgsman
Session: Poster Display session 2
Resources:
Abstract
5865 - Patients with a 21-gene assay in South East London differ from the TAILORx trial population
Presenter: Charalampos Gousis
Session: Poster Display session 2
Resources:
Abstract
1312 - Predictive tools in adjuvant breast cancer – what is the standard of evidence supporting their utility? A literature review examining validation of Adjuvant!, Cancermath and NHS Predict
Presenter: Alice Loft
Session: Poster Display session 2
Resources:
Abstract
2445 - Oncologic outcome of invasive lobular carcinoma: Is it different from that of invasive ductal carcinoma?
Presenter: Hee Jun Choi
Session: Poster Display session 2
Resources:
Abstract
2476 - Pathologic response and survival efficacy in patients with initial nodal involvement after neoadjuvant chemotherapy in early breast cancer
Presenter: SERAFIN MORALES Murillo
Session: Poster Display session 2
Resources:
Abstract
3761 - Chemotherapy-induced amenorrhea: prognostic impact on premenopausal Egyptian patients with breast cancer
Presenter: Khaled Abdel Karim
Session: Poster Display session 2
Resources:
Abstract
4687 - Predicting the presence of breast cancer using circulating small RNA in the serum
Presenter: Yumiko Koi
Session: Poster Display session 2
Resources:
Abstract